Granules India and Ajinomoto OmniChem create jv in India

Published: 18-Jul-2011
Manufacturing Ingredients Finance Pharmaceutical

Granules OmniChem will operate an API and intermediates facility in Vishakhapatnam, Andhra Pradesh

Belgian chemicals company Ajinomoto OmniChem and Indian pharmaceuticals manufacturer Granules India have formed a 50:50 joint venture to produce active pharmaceutical ingredients (APIs) and intermediates for third parties.

The new company, Granules-OmniChem, will build a US$20m plant in the Pharmacity SEZ zone in Vishakhapatnam, Andhra Pradesh, initially to manufacture high-value, low-volume APIs and intermediates.

Construction of the facility will start in November and should be completed towards the end of 2012.

The jv aims to capitalise on demand from pharmaceutical firms which are outsourcing their manufacturing needs at a time when the industry is focused on the US$234bn generics market. More than 80% of API production is for the generics market.

Granules-Omnichem will focus on producing APIs and intermediates for existing customers of both partners and in the future manufacture new chemical entities.

‘Our shareholders will benefit since this will enable Granules to diversify its business by offering high value APIs and intermediates which will increase our profitability,’ said Krishna Prasad, managing director of Granules.

Gwin Bompas, managing director of Ajinomoto OmniChem, which employs around 700 people at three sites in Belgium, said the jv would enable the firm to ‘offer access to quality medicine at an affordable price for the market’.

Granules India manufactures finished dosage forms, pharmaceutical intermediates and APIs, which are distributed in more than 50 countries.

See more

You may also like

Manufacturing

Ajinomoto Bio-Pharma Services buys out joint venture company

Read more
The purchase will transfer the remaining 50% ownership of Granules OmniChem from Ajinomoto’s joint venture partner, Granules India

Trending Articles

  1. Nemera partners with Therakind to expand nasal drug delivery portfolio with DriDose dry powder platform The manufacturer has announced a strategic partnership with UK pharmaceutical company Therakind to advance the DriDose intranasal dry powder platform, adding dry powder delivery capabilities to complement Nemera's existing liquid nasal formulation offering
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Accelerating the development of bispecific antibodies Sherry Gu, Executive Vice President and CTO at WuXi Biologics, explains how the use of comprehensive tailored approaches can enhance bispecific antibody productivity, stability and quality while accelerating their delivery to market
  3. Simplifying continuous operations: lowering the barrier to faster development Continuous manufacturing has long promised faster development, improved process understanding and, in the absence of scale-up, smoother commercialization. For many pharmaceutical R&D teams, those benefits are well understood. What still holds them back, however, is not scepticism about the concept; it’s the perceived effort required to implement it
  4. dsm-firmenich launches ModulaSENSE Bitter to tackle bitterness in oral drug formulations The new taste modulation technology combines bitter blockers, maskers and sweeteners with receptor-based analysis to help pharmaceutical formulators improve the palatability of oral medicines

Upcoming event

Making Pharmaceuticals

21–22 April 2026 | Exhibition | Coventry, UK See all

You may also like

Manufacturing

Ajinomoto Bio-Pharma Services buys out joint venture company

The purchase will transfer the remaining 50% ownership of Granules OmniChem from Ajinomoto’s joint venture partner, Granules India
Finance

Indian Big Pharma companies buck the global economic trend

India\'s top 25 pharma companies continue to go from strength to strength
Manufacturing

Biopharma firms favour European contract manufacturing over US sites despite tariff pressure

US contract manufacturing deals for FDA-approved drugs hit a five-year low in 2025, as biopharma companies (including major US-headquartered firms) increasingly direct outsourced production to European facilities, new GlobalData analysis reveals
Manufacturing

Touchlight partners with SVF Vaccines to advance dual hepatitis B/D vaccine into clinical development

The pair will progress an innovative dual-targeting hepatitis B and D vaccine into clinical trials, leveraging Touchlight's enzymatic doggybone DNA platform, which has demonstrated significant dose-sparing potential compared to traditional plasmid DNA
Pharmaceutical

From complexity to confidence: Smurfit Westrock finds a better way to ensure accuracy with EyeC

Demands for printing perfection and regulatory compliance, Smurfit Westrock faced growing complications in producing multilingual pharmaceutical inserts
Research & Development

Oxford BioTherapeutics signs T-cell engager collaboration with Bristol Myers Squibb for solid tumour targets

The company has entered a multi-year collaboration with BMS to discover and develop next-generation T-cell engager therapies for solid tumours using its OGAP-Verify platform, marking the company's third major pharma partnership in twelve months following deals with GSK and Roche
Manufacturing

An integrated path: how CDMOs are reshaping complex drug development

The pharmaceutical CDMO sector is rapidly evolving toward integrated, end-to-end partnerships that align development, manufacturing, packaging and supply to meet the growing complexity, cost pressures and scalability demands of advanced biologics and precision therapies
Subscribe now